Randomized Trial Using Standard Dose Versus High Dose Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Diffuse Large B Cell Lymphomas.

Trial Profile

Randomized Trial Using Standard Dose Versus High Dose Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Diffuse Large B Cell Lymphomas.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Rituximab (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Primary endpoint (Disease-free survival rate) has not been met, as per the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 22 Jun 2012 Actual end date (1 Jun 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top